Strategic Synergy Post-acquisition by SSI Strategy, NDA Group offers integrated regulatory, clinical development, medical affairs and commercial planning services, enabling cross-sell opportunities to biotech clients seeking end-to-end support.

Nordic Accelerator NDA Accelerator in the Nordics positions the firm as a go-to partner for Nordic market access, offering faster, compliant regulatory pathways and a foothold to expand services to nearby European markets.

Global Reach With 25+ years of regulatory experience and a global network, NDA Group can help clients expedite filings and approvals in key markets worldwide, appealing to biotechs aiming for rapid multi-market authorization.

Leadership Momentum Recent leadership hires and advisory board expansions—CFO appointment and oncology-focused advisors—signal investment, credibility, and capability to attract mid- to late-stage biotech clients, especially in oncology.

Financial Stability As a mid-sized firm with 25-50M revenue and 51-200 employees within the SSI Strategy ecosystem, NDA Group offers capacity and stability to support growing biotech programs and complex regulatory campaigns.